Trial: 201908202

A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase

II/III

Principal Investigator

Park, Haeseong

Disease Site

Esophagus; Stomach

Learn more about this study at: clinicaltrials.gov